Kazia Therapeutics Limited (NASDAQ:KZIA – Get Rating) saw a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 19,000 shares, a decline of 21.2% from the May 15th total of 24,100 shares. Based on an average daily trading volume, of 27,500 shares, the days-to-cover ratio is currently 0.7 days.
Institutional investors and hedge funds have recently bought and sold shares of the company. Morgan Stanley grew its position in shares of Kazia Therapeutics by 22.8% in the third quarter. Morgan Stanley now owns 287,346 shares of the company’s stock valued at $3,253,000 after purchasing an additional 53,393 shares during the last quarter. Envestnet Asset Management Inc. acquired a new position in Kazia Therapeutics during the 4th quarter valued at about $223,000. Susquehanna International Group LLP lifted its position in shares of Kazia Therapeutics by 107.2% during the 4th quarter. Susquehanna International Group LLP now owns 50,762 shares of the company’s stock worth $429,000 after buying an additional 26,267 shares in the last quarter. Finally, Citadel Advisors LLC bought a new stake in Kazia Therapeutics during the 2nd quarter valued at $126,000. 3.60% of the stock is owned by institutional investors.
NASDAQ KZIA traded down $0.15 during mid-day trading on Thursday, reaching $5.25. 9 shares of the company’s stock traded hands, compared to its average volume of 24,532. Kazia Therapeutics has a 1-year low of $5.01 and a 1-year high of $12.28. The company has a fifty day simple moving average of $6.33 and a 200-day simple moving average of $7.09.
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer.
- Get a free copy of the StockNews.com research report on Kazia Therapeutics (KZIA)
- The Q2 Earnings Season Could Be A Bloodbath
- Commercial Metals Company Is Ready To Rebound
- The Institutions Turn The Tide For Jabil
- A10 Networks: Key 5G Infrastructure Stock that’s Beating the Market
- Allstate: A Safe Stock During Volatile Times, Which Will Benefit From Rising Rates
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.